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The most severe manifestations of malaria (caused by Plasmodium falciparum) occur as
a direct result of parasitemia following invasion of erythrocytes by post-liver blood-stage
merozoites, and during subsequent cyto-adherence of infected erythrocytes to the vascular
endothelium. However, the disproportionate epidemiologic clustering of severe malaria
with aggressive forms of endemic diseases such as Kaposi’s sarcoma (KS), a neoplasm that
is etiologically linked to infection with KS-associated herpesvirus (KSHV), underscores the
signiﬁcance of previously unexplored co-pathogenetic interactions that have the potential
to modify the overall disease burden in co-infected individuals. Based on recent studies
of the mechanisms that P. falciparum and KSHV have evolved to interact with their mutual
human host, several newperspectives are emerging that highlight a surprising convergence
of biological themes potentially underlying their associated co-morbidities. Against this
background, ongoing studies are rapidly constructing a fascinating new paradigm in which
themajor host receptors that control parasite invasion (Basigin/CD147) and cyto-adherence
(CD36) are, surprisingly, also important targets for exploitation by KSHV. In this article,
we consider the major pathobiological implications of the co-option of Basigin/CD147 and
CD36 signaling pathways by both P. falciparum and KSHV, not only as essential host factors
for parasite persistence but also as important mediators of the pro-angiogenic phenotype
within the virus-infected endothelial microenvironment. Consequently, the triangulation
of interactions between P. falciparum, KSHV, and their mutual human host articulates a
syndemic relationship that points to a conceptual framework for prevalence of aggressive
forms of KS in malaria-endemic areas, with implications for the possibility of dual-use
therapies against these debilitating infections in resource-limited parts of the world.
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INTRODUCTION
Plasmodium falciparum (Pf) malaria is one of the world’s lead-
ing health challenges, and at least two million people, mainly
children below the age of 5 years, die each year from clinical
complications of the disease (Snow et al., 2005). The most severe
manifestations of Pf malaria occur as a direct result of parasitemia
following invasion of erythrocytes by post-liver blood-stagemero-
zoites, and during subsequent cyto-adherence of parasitized red
blood cells (pRBCs) to the vascular endothelium and other host
cells and tissues. Erythrocyte invasion is executed by a family
of Pf reticulocyte-binding-like homolog (PfRh) ligands displayed
on the surface of merozoites. Among at least ﬁve known mem-
bers of this family, PfRh5 (Rodriguez et al., 2008; Lopaticki et al.,
2011; Tham et al., 2012), which is indispensable for merozoite
growth in cultures, is essential for invasion by all Pf strains
(Baum et al., 2009; Lopaticki et al., 2011). The cognate ery-
throcyte receptor for PfRh5 was recently identiﬁed as CD147
[also known as Basigin (BSG), extracellular matrix metallopro-
teinase inducer (EMMPRIN), and leukocyte activation antigen,
M6 (hereafter CD147); Crosnier et al., 2011]. This discovery is
notable for the fact that the CD147/PfRh5 pair is essential for
invasion of all laboratory-adapted and ﬁeld strains of Pf, a cross-
strain dependency that reveals opportunities for new anti-malarial
therapies based on targeting this receptor/ligand interaction. Fol-
lowing invasion, extensive replication within infected human red
blood cells (RBCs) results in surface expression of the multi-
domain Pf erythrocyte membrane protein-1 (PfEMP-1) family
of genes (Baruch et al., 1995), including PfEMP-1 that serves as
a platform for sequestration of pRBC from the blood circula-
tion by adhering to endothelial and other host cells and tissues
(Berendt, 1993).
The cyto-adhesive property of infected red blood cells to
the microvasculature and sequestration within vital organ sys-
tems is an important survival strategy that allows the parasite
to escape immune-mediated destruction (Urban et al., 1999).
Cyto-adherence is mediated by an orchestrated set of interac-
tions between speciﬁc regions within the ectodomain of PfEMP-1
[notable among them being the cysteine-rich interdomain region
(CIDR1α)], with a variety of host molecules on the surface of
capillary endothelial cells. A well-characterized host receptor that
mediates cyto-adherence of most Pf isolates to the peripheral vas-
culature is humanCD36 (Ockenhouse et al., 1989), although other
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cell adhesion molecules are also involved in execution of strain
and tissue-speciﬁc cyto-adhesive events (Ockenhouse et al., 1991;
Baruch et al., 1997; Figure 1).
Recent studies have revealed that while erythrocyte invasion
and cyto-adherence represent essential evolutionary strategies for
parasite growth, survival, and persistence, they are also invari-
ably associated with alteration of cellular physiology, which in
turn may contribute directly to the deﬁning clinical manifes-
tations of Pf infection (Trossaert et al., 1991; Fried and Duffy,
1998). However, less examined is the provocative hypothesis
that malarial disease may not be solely attributable to compli-
cations associated with the various stages of the Pf lifecycle alone;
rather, the sequelae of illnesses associated with Pf malaria is
likely to be the collective manifestation of a multitude of com-
plex interactions between Pf, other co-pathogenic infections, and
the human host. In this article, we highlight emerging evidence
supporting the proposition that the signaling pathways anchored
by Basigin/CD147 and CD36, two of the known host recep-
tors that control Pf invasion and cyto-adherence, respectively,
are also targets for functional subversion by Kaposi’s sarcoma
(KS)-associated herpesvirus (KSHV), an inherently persistent
cancer-associated herpesvirus that is prevalent inmalaria-endemic
regions. We discuss a number of surprising nodes of pathogenetic
FIGURE 1 | Basic interactions of P. falciparum with human erythrocytes
during invasion (A) and with blood capillary endothelium during
cyto-adherence (B). Upon exit from the liver, invasion of red blood cells by
the blood-stage merozoites leads to replication and subsequent surface
expression of the multi-domain PfEMP-1 molecule that mediates
cyto-adherence via the binding activities of DBL1, CIDR1, and DBL2
domains of PfEMP-1 with various host adhesion receptors. Shown here is
a region of PfEMP-1 encoded by FCR3S1.2-var1 (Chen et al., 2000). The
CIDR1 domain primarily binds to CD36 and to members of the
immunoglobulin superfamily, including IgM and CD31/PECAM (platelet
endothelial cell adhesion molecule), whereas the DBL2 domain binds
mainly to CD31/PECAM-1.
interface between Pf and KSHV in this context, and evaluate
the major implications of the apparent co-option, by both Pf
and KSHV, of CD147 and CD36 signaling pathways as a means
to promote Pf persistence on one hand, and virus-induced reg-
ulation of the angiogenic phenotype, on the other. We then
provide a synthesis of how the triangulation of interactions
between Pf, KSHV, and their mutual human host represents the
basis for a venerable syndemic relationship that may explain
the co-incidence of aggressive forms of KS in malaria-endemic
regions.
THE MULTI-FACTORIAL ETIOLOGY OF KAPOSI’S SARCOMA
The most important pathological manifestation of KSHV infec-
tion is KS, a multifocal and highly angiogenic mesenchymal
neoplasm characterized by profound inﬂammation and angio-
proliferative expansionof spindle cells believed to be of endothelial
origin (Bubman and Cesarman, 2003). KS occurs in at least four
epidemiological forms, each with its own distinguishing clini-
cal disposition determined by age, sex, geographical location,
socio-economic status, previous exposure to parasitic infections,
co-infection with the human immunodeﬁciency virus (HIV), and
the extent of acquired or iatrogenic immunosuppression (Bubman
and Cesarman, 2003; Dourmishev et al., 2003; Haverkos, 2008):
thus, iatrogenic KS is mostly associated with organ (especially
renal) transplantation and is mostly seen as localized skin lesions
among people from areas where KSHV is endemic. Epidemic
HIV/AIDS-associated KS is more commonly seen among HIV-
infected individuals, while classical KS (cKS) manifests among
older men of Mediterranean origin as red to purple skin plaques
or nodules primarily on the lower extremities. Endemic KS (eKS),
which is strikingly similar to cKS in its clinical disposition, is highly
prevalent in East and Central Africa, where it affects children and
young adults as a cutaneous disease invading soft tissue and bone,
or as a fulminant lymphadenopathy that can rapidly disseminate to
visceral organs (Hengge et al., 2002a,b). eKS is currently the most
common cancer in adult East and Central African men and fol-
lows only cervical and breast cancer in adult women (Bassett et al.,
1995; Wabinga et al., 2000; Casper, 2006). An important distinc-
tion is that whereas iatrogenic and AIDS-related KS are invariably
associated with an immunosuppressed state, cKS and eKS are gen-
erally not (Kestens et al., 1985), implying that the development
and/or propagation of the latter two types of KS (i.e., cKS and
eKS) may be controlled by unique, geographically restricted co-
factors unrelated to HIV or drug-induced immune suppression
(Pyakurel et al., 2007).
A number of non-competing hypotheses have been proposed
to explain the contribution of socio-economic, behavioral, and
environmental co-factors to the histogenesis of eKS and cKS, the
two types of the lesion not strictly dependent onHIV or iatrogenic
immunosuppression. For example, clinical studies have revealed
that eKSdisplays a notable predilection for the feet and legs of rural
peasants and cultivators living in highland areas, thus inspiring the
volcanic soil hypothesis ﬁrst proposedbyZiegler (1993) and subse-
quently supported by additional epidemiologic studies (Montesu
et al., 1995; Montella et al., 1996, 1997, 2000; Goedert et al., 2002).
This hypothesis proposes that walking barefoot allows soil-borne
aluminosilicates, iron oxides, and other clay minerals to be taken
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up through sweat glands and abrasions by resident macrophages,
dermal microvascular endothelial cells, and by the lymphatic sys-
tem. The resulting chronic lymphatic irritation, inﬂammation,
and immune suppression could in turn support primary infection
through these portals, and/or reactivation of latent KSHV within
the epidermal aspects of skin. Lin and colleagues also recently sug-
gested that exposure to soil and water constituted an additional
risk factor for KS development by promoting parasitic infections
that could either reduce local immune reactivity or induce a con-
dition of inﬂammation necessary for KS development as well (Lin
et al., 2008). Alternatively, the ﬁnding that some natural products
of plants indigenous to the areas with eKS could reactivate KSHV
(Whitby et al., 2007) inspired the “oncoweed” hypothesis of KS
development. Subsequently, Ruocco et al. (2011) noted that qui-
nine, an anti-malarial drugused extensively as one of themainstays
for treatment of malaria in immunocompetent children,may trig-
ger KS development via its immunosuppressive effects that could
support virus reactivation. It is therefore noteworthy that although
available evidence is not sufﬁcient to explain the distinctive geo-
graphical distribution of KS, the four known types of the lesion
have a multi-factorial etiology, with the unifying theme being that
the potential co-factors in each case operate at the level of the
molecular mechanisms that control KSHV infection, dissemina-
tion, and the balance between virus replication and establishment
of latency. This is a relevant link given the fact that a sustained
state of low level lytic replication may be important for histoge-
nesis and probably propagation of the KS lesion (Grundhoff and
Ganem, 2004).
CO-PATHOGENIC MECHANISMS OF KS AND MALARIA: A
HYPOTHESIS
Like Burkitt’s lymphoma, KS is one of the most prevalent child-
hood cancers in malaria-endemic areas. The incidence of KS
displays a considerable degree of geographic variation thatmirrors
the prevalence of its causative agent, and may depend on etiologic
mechanisms that are controlled by geographically restricted co-
factors, including malaria endemicity (Ziegler et al., 1984, 2003;
Ascoli et al., 2001, 2006a,b; Coluzzi et al., 2003, 2004b; Wakeham
et al., 2011). For example, KS incidence is particularly high in
sub-Saharan Africa, a region with one of the highest rates of
malaria deaths (Snow et al., 2005). Epidemiological studies have
also shown a disproportionately high incidence of KS among
elderly men in Greece, Turkey, Israel, and in Italy where the great-
est number of recorded cases are in the formerly malaria-endemic
provinces of Sardinia, Sicily (Vitale et al., 2001), and in the Po
valley (Ascoli et al., 2001). Such overlapping geographic clustering
of Pf malaria with eKS or cKS has inspired the co-pathogenesis
hypothesis, which proposes that a previous or ongoing expo-
sure to KSHV in a setting of underlying parasite persistence (or
vice versa) may result in molecular interactions between Pf and
KSHV that could modify the overall disease burden exerted by
both pathogens at a micro level. Based on this attribution, we refer
to the putative co-morbidity of KS and Pf malaria (in settings
for which the evidence for this linkage is strong), as represent-
ing an example of a classic syndemic relationship articulated by
the display of co-incident clustering within deﬁned geographic
regions.
In spite of evidence from case–control studies that show a
disproportionately high KS prevalence in areas of currently or
previously high malaria endemicity, a molecular link between KS
pathogenesis and Pf malaria has not been rigorously examined at
a micro level, and the correlation is even more difﬁcult to estab-
lish at a population level because of the indeterminate nature of
the mechanisms by which malaria might inﬂuence KS pathogen-
esis outside the known clusters of endemic disease co-incidence.
On one hand, the role of malaria as a co-factor for eKS has been
hypothesized based on the potential of the Anopheles mosquito
vector to contribute to person-to-person spread of KSHV, and to
establish an immunosuppressed state at the site of the mosquito
bite, which would then create a local permissive environment for
KSHV infection (Coluzzi et al., 2003;Ascoli et al., 2006a,b,c). How-
ever, we propose an alternative model based on the provocative
hypothesis that both the malaria parasite and KSHV exert bidi-
rectional inﬂuences upon each other that operate at a much more
complex level beyond the permissive beneﬁts of immune suppres-
sion or the modifying effects of occupational, socio-economic, or
environmental co-factors.
As a conceptual basis for our hypothesis, consideration of some
of the known molecular controls that regulate the KSHV life cycle
reveals a number of insights into the potential pathobiological
link between KS and malaria. Like Epstein–Barr virus (EBV) and
related herpesviruses, KSHV establishes both lytic and long-term
latent infections, the balance between which determines the tim-
ing and intensity of pathologic outcomes in speciﬁc organ systems.
Interestingly, bothKSHV and EBV are highly prevalent inmalaria-
endemic areas and also share many features in their life cycles,
including the manner in which they regulate the molecular switch
between latency and lytic replication. For example, expression of
the major KSHV replication and transcription activator (RTA) is
essential for virus replication and dissemination, and is depen-
dent on activation of p38 and extracellular signal-related kinase
1/2 (ERK1/2) mitogen-activated protein kinase (MAPK; Xie et al.,
2008). KSHV RTA is the genetic and functional homolog of EBV
RTA/BRLF1 (Bam HI fragment Z rightward open-reading frame
1) which, in concert with Zebra Transcriptional Activator/BamHI
fragment Z rightward open-reading frame 1 (ZTA/BZLF1), can
initiate EBV lytic cycle (Staudt and Dittmer, 2007). KSHV RTA
positively regulates immediate and delayed early promoters as
well as its own promoter by interacting with cellular transcrip-
tion factors such as activator protein-1 (AP-1), octamer binding
transcription factor 1 (Oct-1), recombination signal-binding pro-
tein Jkappa (RBP-Jκ), andCCAAT/enhancer binding protein alpha
(C/EBPα; Staudt and Dittmer, 2007); in this way, RTA is suscep-
tible to a variety of signal transduction pathways that are likely to
activate its promoter. In fact, KSHVRTA expression (and therefore
lytic replication) can be induced in vitrousing a variety of chemical
compounds such as ionomycin (a calcium ionophore), sodium n-
butyrate (NaB, a histone deacetylase inhibitor) and phorbol esters
such as 12-O-tetradecanoylphorbol-13-acetate (TPA), all of which
can also be used to induce EBV lytic cycle (Luka et al., 1979; Renne
et al., 1996; Zhu et al., 1999; Gao et al., 2001).
Given the shared genetic and biological properties of EBV and
KSHV, it is not surprising that the two viruses can co-exist as
latent episomes in certain peripheral effusion lymphoma-derived
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cell lines (Horenstein et al., 1997). They also display similarities not
only in themechanismof induction of the lytic cycle but also in the
distribution of endemic cancers associated with them in regions of
high malaria endemicity, which perhaps reﬂects the contribution
of malaria as a common co-factor in the pathogenesis of cancers
associated with these viruses. For EBV, the epidemiological associ-
ation between malaria and African endemic Burkitt’s lymphoma
(eBL) is well established (Moormann et al., 2011), although the
molecular mechanisms by which malaria modiﬁes eBL and other
pathobiological outcomes of EBV infection remain a matter of
intense investigation (Rochford et al., 2005). Interestingly, eBL is a
B cell lymphoma propagated by a deregulation in the c-myc onco-
gene as a result of chromosomal translocation, and although EBV
is a necessary etiological agent for eBL, it is clearly not sufﬁcient in
absence of other essential co-factors. It is also worth noting that
whereas nearly all African children in endemic areas suffer from
several malaria episodes as a result of chronic exposure to Pf, only
a fraction of them show signs of severe, life-threatening forms
of the disease, implying that the biological processes underlying
the progression of infection to disease are much more complex.
Interestingly, EBV is ubiquitous in the general human population,
and in children living in malaria endemic areas, primary infection
can occur within a few months of birth (Piriou et al., 2012), and
may seroconvert within 3 years after primary infection, followed
by a tightly orchestrated viral latency state in memory B cells that
reﬂects the balance between viral replication and host immune
control. Emerging new evidence now suggests that the exit from
latency to the viraemic state that supports eBL development may
be impacted at a molecular level by the replicative blood-stage
form of the parasite life cycle. Thus, Chene et al. (2007) recently
demonstrated that interactions between the CIDR1α domain of
PfEMP-1 on the surface of pRBCs, with a cognate surface recep-
tor(s) expressed on the surface of EBV-infected humanmemory B
cells, stimulates B cell proliferation (as previously shown; Donati
et al., 2004) and reactivates EBV not only from the chronically
infected Akata cell line but also from latently infected B cells iso-
lated from the peripheral blood and tonsils of healthy EBV carriers
(Chene et al., 2007). The mechanism by which conjugation of
PfEMP-1-expressing pRBCwith EBV-infected B cells triggers virus
replication in this model remains to be elucidated, but the conse-
quences of this interaction can be readily appreciated as providing
a possible explanation for the increased EBV viral load that con-
stitutes risk for eBL among children living in areas of high malaria
endemicity.
Remarkably, we have also discovered that cross-linking of CD36
on the surface of KSHV-infected cells with MC179, a recom-
binant peptide derived from the CIDR1α domain of PfEMP-1
that normally interacts with CD36 to mediate cyto-adherence
(Ockenhouse et al., 1989, 1991; Baruch et al., 1997), not only
upregulated CD36 expression (Figure 2A) but also reactivated the
virus from latency through transcriptional activation of KSHV
RTA (Figure 2B), and that the molecular mechanisms that control
this process overlap with those that putatively regulate PfEMP-1-
dependent EBV reactivation from latently infected cells (Chene
et al., 2007). Remarkably, structural mimics of MC179, includ-
ing the two helical heptad repeats (HR1 and HR2) derived
from KSHV entry glycoprotein B (gB) also upregulated CD36
FIGURE 2 | (A) Upregulation of CD36 by both the PfEMP-1-CIDR1α-derived
MC179 peptide (lanes 5 and 6) and by KSHV gB-derived heptad peptide
ligands HR2 (lanes 3 and 4), and the less potent HR1 (lanes 1 and 2) are
both blocked by a monoclonal anti-CD36 antibody. Note that anti-CD36 did
not block control upregulation of CD36 in response to treatment with
sodium butyrate (NaB; lanes 7 and 8). (B) Activation of KSHV RTA by
MC179 occurs via a CD36-dependent mechanism that can be blocked by
anti-CD36 antibody FA6-152. Methodology : brieﬂy, melanoma-derived
Mel1700 cells were seeded in a six-well plate and either left untreated or
pre-incubated with 10 μg/ml of anti-CD36 monoclonal antibody clone
FA6-152 for 25 min. at 25◦C. After washing to remove excess antibody,
cells were incubated with either 100 μg/ml of KSHV gB-derived HR1,
200 μg/ml HR2 peptide, 100 μg/ml recombinant MC179, or 2 mM sodium
butyrate (NaB). Forty-eight hours after treatment, total RNA was isolated
and used as template in semi-quantitative RT-PCR with primers to an
internal fragment of human CD36, viral RTA, or human glyceraldehyde
3-phosphate dehydrogenase (GAPDH) loading control. (C) Speciﬁc
activation of the KSHV lytic switch protein, RTA, by the PfEMP-1-CIDR1α-
derived peptide MC179 from Pf Malayan Camp strain, but not by peptides
derived from CIDR1α domains of A4tres (which binds ICAM-1) or the
Vietnam Oak Knoll strain (FVO).
expression and further induced virus reactivation in a CD36-
dependent manner. Indeed, like MC179, the effect of these helical
peptides could be blocked by a monoclonal antibody to CD36
(Figures 2A,B), suggesting that they bind a region on the exoplas-
mic face of CD36 that overlaps with MC179. It is also insightful
that the KSHV lytic cycle was activated only by the PfEMP-1-
CIDR1α-derived peptide from Pf Malayan Camp strain, but not
by peptides derived from the Vietnam Oak Knoll (FVO) or A4tres
strain [that preferentially binds intercellular adhesion molecule 1
(ICAM-1) and not CD36] (Figure 2C), demonstrating that reac-
tivation of KSHV by the parasite ligand displays some degree of
strain speciﬁcity for Pf that is associated with severe malaria in
Africa.
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Since CD36 mediates parasite persistence by mediating cyto-
adherence and sequestration of parasitized erythrocytes away
from immune surveillance, the ability of MC179 to stimulate
KSHV reactivation is signiﬁcant, as it supports a model whereby
in vivo cross-linking of CD36 on the surface of KSHV-infected
cells, either by its natural ligand(s) or upon conjugation with
the CIDR1α domain of PfEMP-1 expressed on the surface of
parasitized erythrocytes (as illustrated in Figure 3), represents a
previously unrecognizedmechanism bywhichKSHV lytic replica-
tion could be induced in the context of a Pf malaria co-infection.
This model provides many new opportunities for experimental
examination of the ability of parasite-derived antigens to reacti-
vate KSHVduring cyto-adherence on the surface of infected blood
endothelial cells and within tissues and organs: (i) Biochemical
analysis of structure/function relationships that control interac-
tions of CIDR1α (and its structural analogs) with CD36, should
reveal potential targets for small-molecule inhibition of parasite-
induced sequestration or reactivation of KSHV in co-infected
individuals. (ii) Elucidation of the signaling mechanisms that reg-
ulate CD36-dependent RTA activation will require multi-pronged
approaches that employ dominant negative versions of the Src-
like kinases such as yes, fyn, and lyn that control down-stream
signaling events initiated by CD36 ligation (see Figure 3). (iii)
Deletional mutagenesis, domain-swapping, functional comple-
mentation, and loss-of-function analysis of genetic mimics of the
recently identiﬁed CD36 polymorphisms that lack the signaling
motif (Aitman et al., 2000; Gelhaus et al., 2001; Chilongola et al.,
2009; Fry et al., 2009) should elucidate the correlates of upstream
signaling networks required for CD36-dependent activation of the
KSHV lytic cycle.
CD36 AND THE Pf LIFECYCLE: IMPLICATIONS FOR KSHV
PATHOGENESIS IN THE CO-INFECTED HOST
CD36 is a class II glycoprotein involved in multiple physiological
functions including cell adhesion, fatty acid uptake, non-opsonic
phagocytosis, and angiogenesis (McGilvray et al., 2000; Podrez
et al., 2007; Silverstein and Febbraio, 2007, 2009). The CD36 struc-
ture consists of a large extracellular loop and two short cytoplasmic
tails at the N- and C-termini (Silverstein and Febbraio, 2009). The
C-terminal tail is involved in signal transduction via association
with Src-like kinases, whereas the extracellular domain contains
binding sites for thrombospondin-1 (TSP-1), a potent natural
inhibitor of angiogenesis (Bagavandoss and Wilks, 1990; Good
et al., 1990; Tolsma et al., 1993), and a variety of other ligands
including the CIDR1α domain of PfEMP-1 (Ockenhouse et al.,
1989). Although CD36 has never been directly associated with
KSHV pathogenesis, some of its pleiotropic functions are con-
sistent with its potential contribution to the basic pathobiology
of KSHV. For example, CD36 is often expressed in association
with signaling structures such as lipid rafts that also contain host
receptors for KSHV entry, including integrins and the KSHV
fusion receptor complex xCT/CD98 (Akula et al., 2002; Kaleeba
andBerger, 2006;Veettil et al., 2006). SinceCD36-mediated signal-
ing may culminate in activation of p38 and ERK MAPK pathways
that overlap with one or more pathways necessary for KSHV
RTA-dependent transcription of viral gene expression (Yipp et al.,
2003; Cohen et al., 2006; Xie et al., 2008), our data suggests that
FIGURE 3 | Hypothetical model of CD36-dependent RTA activation. A
motif displayed by PfEMP-1 on the surface of parasitized erythrocytes
interacts with its cognate epitope within the ectodomain of CD36 on the
surface of microvascular endothelial cells. This interaction activates one or
more of the Src-like kinases, which in turn initiate a phosphorylation
cascade that results in p38 and ERK/MAPK activation. This process
culminates in activation of a cellular transcription factor, likely AP-1 (dimer
of c-jun and c-fos), which translocates into the nucleus and stimulates
KSHV RTA-dependent transcription of viral lytic cycle genes, starting with
immediate early (IE), which then activate delayed early (DE), followed by
late structural genes involved in assembly of an infectious virus particle.
CIDR1α-dependentRTAactivationmay occur via by signals trans-
duced through CD36 (Figure 3). However, our model also raises
many signiﬁcant questions: (a) Does CIDR1α-induced KSHV
replication involve mechanisms that overlap with, or distinct from
those that support CIDR1α-induced EBV replication (Chene et al.,
2007)? (b) Does it require the traditional CD36-regulated recruit-
ment of Src-like kinases and subsequent phosphorylation of p38
and ERK MAPK? (c) Does it directly result in downstream activa-
tion of a speciﬁc cellular transcription factor such as AP-1 that is
known to activate KSHVRTA (or EBV ZTA) promoter(s) (e.g., see
Figure 3)? (d) Is it strictly dependent on interactions of CIDR1α
with a distinct epitope on CD36, or does it overlap with, and
is therefore also inducible by, other CD36 ligands such as TSP-
1? Investigation of the role of TSP-1 in this context is relevant,
given that TSP-1 is present in high concentrations in human saliva
(Crombie et al., 1998, 2001; Shugars, 1999) that generally contains
signiﬁcant levels of KSHV virions shed from the underlying oral
zones of carriers (Pauk et al., 2000; Coluzzi et al., 2004a; Chene
et al., 2007; Hadinoto et al., 2009). Critical new experiments that
address these derivative questions represent an exciting area of
research into the molecular basis for the emerging new paradigm
of co-pathogenesis. It is also anticipated that isolation of poly-
morphisms in CD36 and other human genes that control host
interactions with Pf, EBV and KSHV may open up additional
opportunities for population-level studies aimed at explaining the
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overlapping distribution of KS, Burkitt’s lymphoma, and malaria
in areas where these diseases display coincident endemicity.
VIRAL SUBVERSION OF THE CD36 SIGNALING PATHWAY:
IMPLICATIONS FOR PARASITE SEQUESTRATION AND
ANGIOGENESIS
Angiogenesis, deﬁned as the development of new blood vessels, is
necessary for growth and proliferation of vascular tumors like
KS, the extent of which is controlled by the balance between
pro-angiogenic and angiostatic elements of the human hemo-
static system. One of the regulatory components of this system is
TSP-1, the angiostatic CD36 ligand known to inhibit endothelial
cell proliferation, migration, and tube formation (Iruela-Arispe
et al., 1991). Remarkably, KSHV upregulates CD36 in melanoma-
derived cell lines but downregulates the protein in endothelial cells
both atmRNA and protein levels (Figure 4). Themechanism(s) by
which KSHV accomplishes these dichotomous, cell type-speciﬁc
effects are not fully understood, but one study recently demon-
strated that KSHV-encoded microRNAs can directly target TSP-1
mRNA for degradation (Samols et al., 2007), ostensibly to pro-
mote an angiogenic growth state of infected cells via attenuation
of the angiostatic effects resulting from interactions between TSP-
1 and CD36. Since the angiostatic signal is associated with viral
lytic replication while the angiogenic phenotype is linked to the
latency phase, virus regulation of CD36 expression and signal-
ing in infected cells implies that the correlates of KSHV latency
are contextually linked to the angiogenic phenotype in disease-
relevant cells. They also provide a potential explanation for our
recent ﬁndings that the KSHV latency program is inefﬁcient in
melanoma cells from which the virus undergoes robust sponta-
neous replication, as opposed to endothelial cells in which the
virus establishes a much tighter state of latency (Fontana et al.,
unpublished ﬁndings).
In addition to direct targeting of TSP-1,KSHVbluntsCD36 sig-
naling in endothelial cells by upregulating the endothelin (ET-1)
system. ET-1 is a pro-angiogenic peptide secreted by the vascular
endothelium and its deregulation is implicated in the pathogenesis
of manymalignancies (Nelson et al., 2003). ET-1 polypeptides and
their cognate receptors are expressed in KS lesions (Nelson et al.,
2003; Basilico et al., 2004), and ET-1 receptor blockade limited
KS cell invasion in an in vivo tumor growth model (Rosano et al.,
2003). The interplay between the pro-angiogenic effects of ET-
1 and the pathophysiology of KS is also encountered in patients
with complicated Pf malaria in which plasma concentrations of
big ET-1, the precursor for bioactive ET-1, are elevated (Wenisch
et al., 1996) as a direct result of cyto-adherence of pRBCs to human
endothelial cells, independent of the parasite strain and regardless
of the origin of endothelial cells (Basilico et al., 2004). There is,
therefore, a signiﬁcant degree of molecular crosstalk between Pf
and KSHV at the level of ET-1 biology. Considered in a broader
context, it is conceivable that by suppressing the angiostatic effects
of CD36 signaling either by reducing CD36 expression, down-
regulation of TSP-1, or via upregulation of ET-1, KSHV could
establish long-term persistence by establishing a state of limited
CD36-dependent viral reactivation, or reduce CD36-dependent
cyto-adherence and consequently limit the frequency of illnesses
associated with this aspect of the parasite life cycle. Unfortunately,
the latter outcomemight be associated with an increase in the like-
lihood for parasite access to the extra-peripheral organs such as
the brain, which may elevate the probability of cerebral malaria.
Although measurement of these parameters in vivo is not trivial,
a number of guiding principles can emerge from in vitro scrutiny
of these molecular interactions based on experimental approaches
that might predict their occurrence in vivo.
CD36 POLYMORPHISMS DO NOT PROTECT FROM MALARIA:
PERSPECTIVES ON SELECTION PRESSURE
It was recently discovered that many people of African origin
harbor a high frequency of mutations and single-nucleotide poly-
morphisms (SNPs) that cause a deﬁciency in the CD36 gene, yet
FIGURE 4 | Cell type-specific outcomes of KSHV infection in skin versus
endothelial cells with respect to CD36 and CD147 expression.
Semi-quantitative RT-PCR (A) andWestern blot (B) analysis of CD147 and
CD36 expression in uninfected (−) versus infected (+) endothelial (lymphatic)
or melanoma-derived Mel1700 cells. KSHV upregulates both CD36 and
CD147 in melanoma-derived cells, whereas in lymphatic and
telomerase-immortalized mixed dermal microvascular and brain endothelial
cells, KSHV upregulates CD147 (conﬁrming a recent study; Qin et al., 2010)
but downregulates expression of CD36 (and its angiostatic ligand, TSP-1; data
not shown); in vivo, these dichotomous effects are consistent with promotion
of angiogenesis, invasion, and tumor metastasis in disease-relevant cell
types.
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they still suffer from severe (particularly cerebral) malaria (Ait-
man et al., 2000; Gelhaus et al., 2001; Chilongola et al., 2009; Fry
et al., 2009). The SNPs found in Kenya and Gambia introduce a
premature stop codon that results in a truncated CD36 protein
lacking the C-terminus and is therefore incompetent for signal
transduction but can still bind its ligand(s), leading to the con-
clusion that mutations that cause CD36 deﬁciency may reduce
CD36-mediated parasite sequestration in peripheral organs but
they may not protect from severe cerebral malaria (Aitman et al.,
2000) that is associated with cyto-adherence to brain endothelium
via interactions of PfEMP-1 with ICAM-1 but not CD36 (Ock-
enhouse et al., 1991). This level of linkage in which mutations
in CD36 – a molecule that is important for parasite persistence –
cause a deﬁciency that does not altermalaria pathogenesis, implies
existence of selection pressures thatmay be induced ormaintained
in the population by an endemic infection (other than malaria)
whose persistence is linked to this genetic output.
The fact that the mutations and their phenotypes occur at high
frequency in malaria-endemic areas with a high prevalence of
viruses associated with endemic cancers underscores a pathobi-
ological paradigm whereby an inherently persistent tumor virus
such as KSHV (or EBV) could provide the selective pressure for
introduction or maintenance of such a mutation into the genetic
registry of populations living in regions of high malaria endemic-
ity. Given thatPfEMP-1 interactionswithCD36 result in induction
of the viral lytic cycle, such a virus-induced genetic output would
conceivably be designed to promote virus escape from immune
surveillance by limiting virus reactivation that might result from
interactions between PfEMP-1 andCD36 on latently infected cells.
The impact of such a genetic inﬂuence, can only be measured
against the host’s ability to restrict virus replication and dissem-
ination, and it could be achieved by interrogating viral genomic
variability or stability in a given population against a proﬁle of
polymorphisms within the genetic registries at the CD36 locus
on a population basis. Availability of patient samples with known
patho-status and disease severity from regions in which the distri-
bution of malaria overlaps with the incidence of virus-associated
endemic cancers would facilitate such a retrospective analysis.
CD147 AND KSHV PATHOGENESIS
CD147 is a widely expressed, type I integral membrane receptor
that belongs to the immunoglobulin (Ig) superfamily (Biswas et al.,
1995). It is over-expressed in a variety of disseminatedhuman solid
cancers and is amajor contributor to themalignant phenotype in a
variety of human cancers (Riethdorf et al., 2006). Signaling events
transduced through CD147 are associated with survival, metas-
tasis, and invasion of a variety of cancer cells, mainly because
it stimulates enhanced stromal release of multiple matrix met-
alloproteinases (MMPs) and vascular endothelial growth factor
(VEGF), which are among the key mediators of angiogenesis
and metastatic transition (Marieb et al., 2004; Tang et al., 2005;
Bougatef et al., 2009; Kanekura and Chen, 2010). CD147 pro-
motes hyaluronan synthesis (Marieb et al., 2004; Slomiany et al.,
2009a), upregulates the Wnt/β-catenin signaling pathway (Sidhu
et al., 2010), and is also involved in epithelial-to-mesenchymal
transition (EMT; Wu et al., 2011). Given the pleiotropic func-
tion of CD147, the signiﬁcance of CD147/PfRh5 interactions in
parasite invasion unlocks new avenues for investigating the nodes
of pathogenetic intersection between Pf malaria and other co-
infecting agents such as KSHV that have evolved mechanisms to
subvert the CD147 signaling pathway to promote their existential
success.
Several layers of this pathogenetic intersection are revealed by
new data on the manner in which both Pf and KSHV have evolved
to exploit CD147 and endothelial cell biology:
a. Whereas endothelial cells play a prominent role as a platform
for cyto-adherence of pRBCs,KSHVdisplays profound tropism
for this cell lineage that represents the basis for origination of
the hyper-proliferating spindle cells characteristically found in
KS lesions (Bubman and Cesarman, 2003; Ganem, 2006).
b. Recent studies demonstrated compelling evidence that de novo
KSHV infection of human endothelial cells as well as oral and
fore-skin-derived ﬁbroblasts results in upregulated expression
of CD147 and that this effect is directly associated with various
virological outcomes consistent with a pro-invasive, migra-
tory, and pro-angiogenic phenotypes (Qin et al., 2010; Dai
et al., 2012a,b). We have also found that KSHV upregulates
CD147 not only in melanoma-derived cells but also in chron-
ically infected lymphatic, microvascular, and brain endothelial
cells (e.g., see Figure 4).
c. Two recent reports showed that KSHV promotes endothelial-
to-mesenchymal transition (endo-MT) through activation of
Notch-dependent signaling events that culminate in stimu-
lation of an invasive phenotype analogous to that orches-
trated by CD147 (Cheng et al., 2011; Gasperini et al., 2012).
KSHV-induced endo-MT was dependent on the activity of
membrane-type-1 MMP (MT1-MMP; Cheng et al., 2011),
which is consistent with a role for CD147 in endo-MT since
MT1-MMP is a CD147-stimulated endopeptidase involved in
extracellular matrix remodeling. It is therefore conceivable that
one of the mechanisms underlying KSHV-induced endo-MT
may involve viral induction of MMP activity (Qian et al., 2007),
likely through upregulation of CD147.
d. CD147 has been implicated in the entry processes of a number
enveloped viruses including HIV-1 (Pushkarsky et al., 2001),
measles virus (Watanabe et al., 2010), and severe acute respi-
ratory syndrome coronavirus (SARS-CoV; Chen et al., 2005).
Based on our recent studies, we also have reason to believe
that CD147 may regulate KSHV entry as well, as an anti-
human CD147 (neurothelin) antibody can potently block
KSHV glycoprotein-mediated fusion, consistent with existence
of CD147 in themembrane of KSHV-permissive cells as part of
a molecular supercomplex (Guo et al., 2000; Yang et al., 2007;
Gallagher et al., 2009) that includes host molecules implicated
in virus entry, such as integrins (Akula et al., 2002) and the cys-
tine transporter complex xCT/CD98hc (Xu and Hemler, 2005;
Kaleeba and Berger, 2006). It is also noteworthy that, like CD36,
CD147 also associates with the xCT/CD98hc complex and con-
fers resistance to some chemotherapeutic drugs (Okuno et al.,
2003; Yang et al., 2007; Zou et al., 2007). Interestingly, another
independent study also demonstrated that the transport activ-
ity of xCT/CD98hc, perhaps in association with CD147, is a
critical correlate of resistance to cisplatin (Huang et al., 2005;
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Singh et al., 2010; Chen et al., 2011; Riglar et al., 2011). For
KSHV-infected individuals, one implication of these molecu-
lar associations could be that virus-induced upregulation of
CD147 (as we and others have shown; Qin et al., 2010; Dai
et al., 2012a,b), could stabilize CD147-containing multi-partite
complexes and in turn potentiate their drug efﬂux functions,
which could blunt the efﬁcacy of chemotherapeutic strategies
that might be used in the treatment of KS and other virus-
associated malignancies. In support of this view, Qin et al.
(2011) recently showed that the intrinsic resistance of KSHV-
positive peripheral effusion lymphomas to the cytotoxic effects
of paclitaxel and doxorubicin depends on orchestrated inter-
actions of CD147 with lymphatic vessel endothelial receptor 1
(LYVE-1) and the homodimeric ATP-binding cassette (ABC)-
G2/BCRP (breast cancer resistance protein) drug transporter
that is highly expressed on the surface of primary effusion
lymphoma (PEL)-derived cell lines.
e. Available evidence suggests that “outside-in” signaling may be
required for the malaria parasite invasion (Singh et al., 2010;
Chen et al., 2011; Riglar et al., 2011), but it remains to be deter-
mined if the structural framework that supports erythrocyte
invasion through CD147 is distinct from, or overlaps with, the
epitope on the CD147 ectodomain that senses signals trans-
duced to endothelial and other cells that express this molecule.
If they are the same,PfRh5-mediated conjugation ofmerozoites
with CD147 on normal or infected endothelial cell surfaces
should result in so-called parasite-to-host “trans-signaling”
events that may lead to untoward pathologic outcomes unre-
lated to parasite invasion itself. Given that PfRh5 has neither
a transmembrane domain nor a cytoplasmic tail, the prob-
ability of trans-signaling is likely to be high since a soluble
form of PfRh5 [existing either as a monomer, as part of a
bioavailable complex with another pathogen molecule such
as PfRipr (Chen et al., 2011), or as bound to a host “han-
dler”] could initiate CD147-dependent signaling outcomes that
are likely to modify Pf malaria or KSHV infection (Marieb
et al., 2004; Xu et al., 2007; Ruiz et al., 2008; Slomiany et al.,
2009b; Sidhu et al., 2010; Wu et al., 2011). A ﬁrst-line exper-
imental testing of such a concept should seek to determine
whether blood-bornemerozoites or soluble forms of PfRh5 can
indeed bind CD147 on KSHV-infected cells and whether those
interactions are directly associated with a CD147-dependent
alteration in cellular behavior, including extracellular remod-
eling and induction of a pro-angiogenic phenotype that is one
of the deﬁning features of the infectious process of KSHV (Qin
et al., 2010; Cheng et al., 2011; Dai et al., 2012a,b; Gasperini
et al., 2012). In Figure 5, we highlight some of the impor-
tant nodes of intersection between KSHV and the malaria
parasite in endothelial cells and skin-derived melanoma cells,
along with their potential impact on the virus life cycle
(i.e., reactivation), KS tumorigenesis, and malaria disease
outcomes.
FIGURE 5 | Cell type-specific outcomes of KSHV interactions with CD36
and CD147 signaling pathways. (A) In melanoma-derived cells (Mel1700),
KSHV upregulates both CD36 (and its ligand, TSP-1) and CD147 (as shown in
Figure 4). Binding of the PfEMP-1 CIDR1α-derived peptide, MC179, to
virus-upregulated CD36 prevents Akt phosphorylation while inducing
RTA-dependent KSHV reactivation via the MAPK/p38 pathway. Remarkably,
structural mimics of MC179, such as the helical heptad repeat (HR) regions
derived from KSHV glycoprotein B (gB), can, like MC179, also induce virus
reactivation in a CD36-dependent manner (as shown in Figure 3). (B) In
lymphatic (LEC) and other endothelial cells such as mixed tolemerase-
immortalized dermal microvascular and brain endothelial cells (tDMB),
KSHV upregulates CD147 but unlike in Melanoma cells, the virus
downregulates both CD36 and its angiostatic ligand, TSP-1; in vivo,
these effects are likely to promote angiogenesis, invasion, and tumor
metastasis. (C) As a key receptor for the merozoite invasion antigen,
PfRh5, KSHV-induced upregulation of CD147 on the surface of infected
endothelial cells increases the frequency of contacts between
merozoite-bound or soluble PfRh5 and blood or dermal microvascular
endothelial surfaces, resulting in induction of CD147-mediated signals that
could alter the microenvironment and cause pathologic outcomes in a variety
of physiological sites in the co-infected
host.
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THERAPEUTIC CONSIDERATIONS FOR KS AND MALARIA:
CHALLENGES AND NEW OPPORTUNITIES
Kaposi’s sarcoma is one of the most frequent neoplasia diagnosed
in malaria-endemic regions of Africa, yet despite recent progress
(Casper, 2006; Casper and Wald, 2007), the landscape of effective
therapeutic strategies for KS remains limited. It is clear that KS
presents in different epidemiologic and clinical forms dictated by
a variety of modifying risk factors, but the lack of data on the rela-
tive contributions of these co-factors in any given epidemiological
setting frustrates efforts aimed at developing new approaches for
clinical management of the disease. Surgical removal of isolated
nodular KS does not eliminate latent KSHV at secondary sites,
while traditional chemotherapy is generally toxic and may have
a high failure rate in HIV-infected patients in whom durable
post-therapy immune reconstitution is improbable. For epidemic
(HIV/AIDS-associated) KS, intervention with the highly active
anti-retroviral therapy (HAART) in HIV/HHV8 (human herpes
virus 8) co-infected patientsmay have contributed to regression of
KS lesions, but the initial success of HAART-based therapy for KS
has been eroded by several concerns. First,HIV is not necessary for
endemic African or classical Mediterranean KS. Second, HAART
only limits the potentiating immunosuppressive effects of HIV but
it does not remove the underlying etiology of KS. Third, HAART
may reduce HIV viral load but it does not restore the entire T
cell repertoire necessary for immunity against KSHV. Fourth, lack
of access to HAART, non-compliance with the treatment, failure
to respond to treatment, and the development of drug-resistant
strains of HIV confound the overall beneﬁt of a strictly HAART-
based approach to KS management. Fifth, the beneﬁts of HAART
are not long-lasting and end up being more detrimental to many
patients with advanced KS who may show no improvement while
remaining in danger of developing post-therapy immune crisis
(Krown et al., 2004). Sixth, the probability of recrudescence of
KS in patients treated with HAART later in life is unpredictable.
There is, therefore, an urgent need for amulti-pronged therapeutic
approach aimed at developing strategies that are appropriate to the
prevailing epidemiologic state of the disease, with the overall goal
being improvement of the treatment outcome for KS patients in
sub-Saharan Africa and other resource-limited parts of the world
(McAllister et al., 2005).
The concept of “angio-therapy” designed to inhibit growth of
angio-proliferative cancers like KS (Tosetti et al., 2002a,b; Ferrari
et al., 2003; Pfeffer et al., 2003) led to the surprising observa-
tion that the anti-malarial peptide artesunate has anti-angiogenic
effects on KS-derived endothelial cell lines (Dell’Eva et al., 2004).
Artesunate is already well tolerated as an anti-malarial drug, and
because it has direct effects against transformed cells, the promise
of its dual use for KS is attractive for co-infected individuals. If
adopted as such, the clinical beneﬁts of artesunate for treatment
of KS would represent a classic illustration of one of the deﬁning
attributes of a syndemic relationship in which the overall clinical
impact of two linked infections (i.e., Pf and KSHV in this case)
can be blunted by targeting the molecular underpinnings that
link the parasite with the disease-modifying inﬂuence of KSHV.
In addition, it has been proposed that quinine and its chloro-
quine and hydroxychloroquine derivatives – drugs that have been
used widely to treat malaria – are immunosuppressive and may,
as such, serve as co-factors for KS by stimulating KSHV reacti-
vation, which would not only promote virus dissemination but
could also support KS histogenesis (Ruocco et al., 2011). However,
the “oncodrug” hypothesis for KS is likely to be more relevant for
individuals with severely altered immunity since, in immunocom-
petent hosts, the viremic state induced by quinine and its derivative
drugs would concomitantly expose hematogenously disseminat-
ing virions to immune surveillance which could in turn limit virus
spread.
With respect to malaria control, approaches that interrupt the
parasite life cycle are ideal, yet in spite of many multi-national
efforts in this regard, successful elimination of the disease remains
a major challenge, as more than half of the world’s population
still lives in areas where there is a risk of contracting the disease.
There are many reasons for this sobering report card, chief among
them being persistent endemicity as a result of drug and insecti-
cide resistance, inadequate support for malaria control programs,
poor environmental management, the complex biology of the dis-
ease, as well as the regional variability not only in the parasite
but also in the nature of its impact on speciﬁc populations and
age groups. Another major challenge remains the lack of practical
and affordable animal models that can faithfully reﬂect mech-
anisms of malaria pathogenesis and immunity in humans. Such
platformswould be valuable for evaluating the efﬁcacy of drug and
vaccine candidates, and for predicting the beneﬁts of drug com-
binations that can maximize safety and efﬁcacy while minimizing
the development of drug resistance.
Given that the invasive asexual blood stage of the Pf life-
cycle is the form associated with symptomatic malaria, recent
efforts toward a malaria vaccine have primarily focused on tar-
geting this stage. In this respect, the discovery of the essential
merozoite invasion receptor increases the number of potential
targets for a second-generation malaria-speciﬁc vaccine based
on CD147/PfRh5 interactions. However, the fact that deletion
of other PfRh proteins also impairs invasion, albeit in a strain-
speciﬁc manner, complicates vaccine design efforts, as it suggests
that the PfRh5/CD147 interaction may be only one of many
ligand–receptor recognition events that must occur during exe-
cution of the invasion process (Cowman and Crabb, 2006; Tanne,
2011; Tham et al., 2012). An approach that targets CD147 may
not be feasible, as it could impact many important physiolog-
ical processes controlled by this molecule. On the other hand,
innovations oriented toward development of vaccine and ther-
apeutic strategies based on the invariant aspects of PfRh5 and
other “accessible” Pf antigens may result in a more meaningful
outcome associated with minimal impact on the human host.
Such strategies may include the combined use of nanovehicle-
deliverable peptide mimetics and single-chain antibodies that can
be administered before or during active parasitemia, or thera-
peutic lentiviral vectors carrying immunogenic epitopes that can
harness the host’s immune capacity. These pathogen-centered
approaches could be used alone or in conjunction with the RTS,S
vaccine that is based on the most prominent surface antigen
of the pre-liver sporozoite stage and which has already shown
some promise in phase III trials (Tanne, 2011). In using PfRh5
as the target, however, the primary goal of any given approach
[antibody-based (Douglas et al., 2011), or otherwise] would be
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to elicit the safest, most long-lasting and most efﬁcacious out-
come that limits the availability of PfRh5 to mediate invasion,
but it must also be guided by the recognition that this antigen
is predominantly located within the rhoptries and it is liberated
and or revealed to the immune system only for a short period
of time when the merozoite contacts the erythrocyte prior to
invasion.
CONCLUSIONS AND FUTURE PERSPECTIVES
Infectious agents have long been implicated in the etiology of a
variety of illnesses, and although recent studies have examined the
role of microbial co-infections in many disease settings, it is not
known whether “cooperative pathogenesis” is sufﬁcient to provide
the driving force behind strategies in which co-pathogenic agents
co-evolve and forge a state of forbearancewith each other andwith
their shared host to advance mutually exclusive existential goals.
Clearly, Pf malaria has been linked to a variety of other infections
that display co-pathogenic relationships with the parasite, notable
among them being eBL (Thorley-Lawson and Allday, 2008), but
recent advances have revealed thatmanyother important examples
of these relationships do exist, and inmost cases they provide a sur-
prisingly informative conceptual window into how co-infections
can modify each other’s disease course. For instance, the recent
elucidation of the molecular mechanisms of erythrocyte invasion
and cyto-adherence has: (a) illustrated the extent to which Pf can
exert its impact on humanphysiology; (b) exposed how alterations
in the expression and function of the host receptors that support
these processes could not only dramatically change the dynamics
of malaria but may also inﬂuence the pathogenesis of other co-
infections such as KSHV that exploit these pathways for existential
beneﬁt; and (c) generated new interest in the structural dispo-
sitions of these receptor/ligand pairs as potential multi-domain
vaccine targets against speciﬁc stages of the Pf life cycle.
Although malaria is not considered a typical opportunistic
infection in the same way that KSHV is, recent advances have
revealed a surprising node of intersection between KSHV and
malaria pathogenesis at the level of the molecular controls that
regulate the persistence of these two highly successful infectious
agents. To the extent that such interactions can be measured at
a micro level, the concept of co-pathogenesis establishes grounds
for the expectation that KSHV and Pf can bidirectionally inﬂu-
ence the clinical course of each other at many physiological levels
leading to a variety of clinical outcomes (Table 1; Figure 5). For
example, CD36-mediated cyto-adherence, by virtue of its ability
to stimulate pathways that overlap with those required for KSHV
reactivation, may contribute to a transient increase in KSHV viral
load anddissemination,which in turn could increase the frequency
of other deﬁning correlates of KSHV-associateddisease that rely on
a viremic state. On the other hand, the pathogenic mechanisms of
a latent KSHV infection, which include KSHV-induced downreg-
ulation of CD36, could effectively alter the overall disease burden
by limiting peripheral sequestration; this could in turn increase
parasitic access to the central nervous system, leading to a higher
probability for cerebral malaria. Ultimately, the emerging picture
supports a syndemic link which, however serendipitous, reveals
a co-evolutionary paradigm centered at the putative dueling role
of CD36 as a mediator of parasite sequestration on one hand and
KSHV replication on the other. In this regard, more extensive
molecular and genetic analysis is required in order to determine
the extent to which KSHV (or EBV, for that matter) might provide
the driving force for altering the genetic registry at the CD36 locus
in regions of high malaria endemicity. It might also be necessary
to analyze the CD36 locus in hematopoietic versus peripheral B
cells that may serve as the vehicle for virus dissemination in vivo,
in order to determine whether infection increases the propensity
for a heritable lesion at this locus.
Table 1 | Summary of the effects of KSHV on CD36 and CD147 expression and signaling, and examples of their potential impact on KSHV and










CD147 Up • Increased angiogenesis through VEGF • Increased trans-signaling by soluble PfRh5
• Increased membrane metalloprotease (MMP) activity
promotes tumor metastasis
CD36 Down • Associated with establishment of latency • Reduced peripheral sequestration





CD147 Up • Indeterminate • Increase in merozoite invasion and para-
sitemia
CD36 Up • The increase in binding of PfEMP-1 to upregulated CD36
leads to virus reactivation
• Increase in CD36/PfEMP-1 binding may
lead to enhanced sequestration of
parasitized erythrocytes
TSP-1 Up • Angiostatic effects of TSP-1 are associated with virus
reactivation
Endothelial cells tested are: HMVEC, human microvascular endothelial cells; t-D/MBEC, immortalized mixed dermal/microvascular brain endothelial cells; and LEC,
Lymphatic endothelial cells. Skin (melanoma)-derived cells tested are Mel1700 and Sk-Mel28 (ATCC). TSP-1, Thrombospondin-1.
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In conclusion, recent advances have revealed several nodes of
pathobiological intersection betweenmalaria and a variety of clin-
ically signiﬁcant infections, and although substantial progress has
been made, we are still in the “embryonic stage” of understanding
how co-infections interact with each other in their mutual host.
Derivative new research emphasis that is inspired by these con-
cepts should include the important goal of developing practical
in vivo platforms (animal models) that could facilitate systematic,
experimental integration of population studies with reduction-
ist multi-component molecular data. Although we are still a long
way from developing such a platform for studying the malaria
and KSHV co-infection paradigm, attempts toward this goal
are an essential step in elucidating the extent to which trian-
gular interactions between Pf, KSHV, and their mutual human
host might articulate a syndemic relationship that underlies the
co-incidence of aggressive KS in parts of the world with endemic
malaria. Once the correlates of co-pathogenesis are isolated, inno-
vative research efforts oriented toward development of effective
“combined” therapies can be launched.
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